CG-BM1
Asset
Allogeneic human bone marrow mesenchymal stem cell therapy intended to treat sarcopenia.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Sarcopenia
Phase 1, Recruiting, NCT07865676, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners1
- Trials1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.